On the stock market since 2012, it operates in the world of health and science. It has 91 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 18% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 97% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 12 months, company executives reported 10 buys and 0 sells. Management buying with its own money is usually read as a good sign.
A loss of $843K against $11.7M in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.02. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
At the current pace of spending, the cash lasts about 1.8 years. After that, the company needs to find new money.
On our five-subject report card, CANN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CANN is a small company that closed last year at a loss. The road back to profit runs through spending discipline.